Neuroprotection: the end of an era.
In: Lancet, Jg. 368 (2006-11-04), Heft 9547, S. 1548
Online
academicJournal
Zugriff:
This editorial reports on stroke research and the use of AstraZeneca, an experimental drug that's been dropped from clinical development. NXY-059 is now a member of a long list of neuroprotective compounds that have failed to be proven clinically useful in the treatment of ischaemic stroke. Researchers are beginning to question whether or not it's useful to pursue neuroprotective strategies for stroke victims. The use of animal models, both financially and ethically, are also being called into question.
Titel: |
Neuroprotection: the end of an era.
|
---|---|
Link: | |
Zeitschrift: | Lancet, Jg. 368 (2006-11-04), Heft 9547, S. 1548 |
Veröffentlichung: | 2006 |
Medientyp: | academicJournal |
ISSN: | 0140-6736 (print) |
DOI: | 10.1016/S0140-6736(06)69645-1 |
Schlagwort: |
|
Sonstiges: |
|